Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. (JNCE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
jnce · stock forecast · 10 analysts (3M) · FMP · updated Apr 29, 2024
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.88
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.88 | ↓ 0.14% |
1-day model range: $1.86–$1.89. Peak: $1.89 (-0.14%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · JNCE · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-02-24 | SMBC Nikko | Downgrade ↓ | Outperform→Neutral |
| 2023-02-23 | Raymond James | Downgrade ↓ | Outperform→Perform |
| 2023-01-03 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-11-11 | Raymond James | Downgrade ↓ | Strong Buy→Outperform |
| 2022-08-31 | Raymond James | Downgrade ↓ | Strong Buy→Buy |
| 2022-08-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-05-23 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-05-11 | Baird | Downgrade ↓ | Outperform→Neutral |
| 2022-05-06 | Raymond James | Maintains | Outperform→Buy |
| 2022-03-16 | SMBC Nikko | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Jounce Therapeutics, Inc. (JNCE) stock. Of the recent 33 rating actions, 2 were upgrades and 10 were downgrades. 10 analysts currently cover JNCE.
Analyst Recommendation Trends
JNCE analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast JNCE EPS of $— for the current fiscal year, based on estimates from 0 analysts. The JNCE revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The JNCE stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus JNCE price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The JNCE short-term stock prediction for tomorrow is $1.88 (-0.14%).
Jounce Therapeutics, Inc. trades on NASDAQ under the ticker JNCE. The JNCE stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
JNCE forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month JNCE price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.88.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.